Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide, Bortezomib

"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"

Trial Locations (9)

13273

Institut Paoli Calmette, Marseille

14076

Centre François Baclesse, Caen

21000

University Hospital of Dijon, Hôpital des Enfants, Dijon

31059

University Hospital of Toulouse, Purpan, Toulouse

33604

"University Hospital of Bordeaux, Hôpital du Haut Lévêque ", Pessac

37044

Hôpital Bretonneau, Tours, Tours

38043

University Hospital of Grenoble, Hôpital A.Michallon, BP 217 X, Grenoble

54511

Hôpitaux de Brabois Nancy, Vandœuvre-lès-Nancy

59037

University Hospital Of Lille, Hôpital Claude Huriez, Lille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

University Hospital, Toulouse

OTHER

NCT01206205 - Frontline Therapy in de Novo Multiple Myeloma Patients Under 65 | Biotech Hunter | Biotech Hunter